Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [1]. Information regarding specific manufacturer coupons for Anoro Ellipta in 2024 is not readily available in the provided text. However, patient assistance programs are often offered for prescription medications.
What is Anoro Ellipta?
Anoro Ellipta is a once-daily, single-inhaler combination medication that contains umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist ( a LABA) [2]. It is prescribed for the long-term, once-daily maintenance treatment of bronchospasm and to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [2].
How can patients get financial assistance for Anoro Ellipta?
Patients seeking financial assistance for Anoro Ellipta may be eligible for GSK's patient assistance programs. These programs are designed to help eligible uninsured and underinsured patients afford their GSK medications [3]. Details on eligibility requirements and application processes are typically available through the manufacturer's website or by contacting GSK directly. Prescription savings cards or coupons can also be a source of cost reduction, though specific 2024 offerings for Anoro Ellipta would need to be verified with the manufacturer or participating pharmacies.
When does Anoro Ellipta's patent expire?
Drug patent information, including expiry dates for Anoro Ellipta, can be complex and subject to change due to various factors such as new patents, patent challenges, and regulatory exclusivities. For detailed and up-to-date patent status information, resources like DrugPatentWatch.com are valuable [4].
What are the alternatives to Anoro Ellipta for COPD treatment?
Other treatment options for COPD include single-agent bronchodilators (LAMAs and LABAs), other LAMA/LABA combination inhalers, inhaled corticosteroids (ICS) in combination with bronchodilators for certain patients, and sometimes triple therapy involving a LAMA, LABA, and ICS. The choice of treatment depends on the individual patient's symptom severity, exacerbation history, and other medical conditions [5].
What are the potential side effects of Anoro Ellipta?
Common side effects reported with Anoro Ellipta include upper respiratory tract infection, pneumonia, bronchitis, sore throat, pain in extremities, muscle spasms, chest pain, atrial fibrillation, constipation, diarrhea, peripheral edema, and blurred vision [2]. Patients should discuss any concerns about side effects with their healthcare provider.
How is Anoro Ellipta administered?
Anoro Ellipta is administered by inhalation using the Ellipta inhaler. Patients are instructed to inhale the medication once daily [2]. Proper technique is crucial for effective delivery of the medication.
---
Sources:
[1] https://www.gsk.com/
[2] https://www.anoroellipta.com/
[3] https://www.gsk.com/en-us/patients/patient-support/
[4] https://drugpatentwatch.com/
[5] https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353419